According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
A number of other research analysts have also recently commented on ADMS. BidaskClub raised Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, February 25th. ValuEngine raised Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, April 1st. Needham & Company LLC cut Adamas Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, March 5th. Mizuho cut Adamas Pharmaceuticals from a neutral rating to an underperform rating and reduced their price objective for the company from $11.00 to $5.00 in a research note on Tuesday, March 5th. Finally, Northland Securities reaffirmed a buy rating and set a $28.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, March 5th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. Adamas Pharmaceuticals currently has an average rating of Hold and an average price target of $20.28.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.13) by $0.05. The business had revenue of $11.67 million for the quarter, compared to analysts’ expectations of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. On average, research analysts anticipate that Adamas Pharmaceuticals will post -3.87 earnings per share for the current fiscal year.
In other news, CEO Gregory T. Went sold 6,319 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total transaction of $50,488.81. Following the transaction, the chief executive officer now directly owns 176,291 shares of the company’s stock, valued at $1,408,565.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 8,361 shares of company stock worth $66,816 over the last ninety days. Insiders own 24.90% of the company’s stock.
Several large investors have recently made changes to their positions in ADMS. Broadfin Capital LLC boosted its holdings in shares of Adamas Pharmaceuticals by 96.8% during the fourth quarter. Broadfin Capital LLC now owns 2,614,468 shares of the specialty pharmaceutical company’s stock worth $22,328,000 after purchasing an additional 1,286,044 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Adamas Pharmaceuticals by 51.7% during the fourth quarter. Macquarie Group Ltd. now owns 2,708,217 shares of the specialty pharmaceutical company’s stock worth $23,128,000 after purchasing an additional 923,099 shares during the period. Deltec Asset Management LLC boosted its holdings in shares of Adamas Pharmaceuticals by 127.4% during the first quarter. Deltec Asset Management LLC now owns 536,836 shares of the specialty pharmaceutical company’s stock worth $3,817,000 after purchasing an additional 300,712 shares during the period. Sectoral Asset Management Inc boosted its holdings in shares of Adamas Pharmaceuticals by 25.5% during the fourth quarter. Sectoral Asset Management Inc now owns 1,133,924 shares of the specialty pharmaceutical company’s stock worth $9,684,000 after purchasing an additional 230,500 shares during the period. Finally, Millennium Management LLC lifted its holdings in Adamas Pharmaceuticals by 91.6% in the fourth quarter. Millennium Management LLC now owns 479,899 shares of the specialty pharmaceutical company’s stock worth $4,098,000 after buying an additional 229,404 shares during the period. 88.03% of the stock is currently owned by hedge funds and other institutional investors.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
See Also: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.